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served for adjunctive therapy for patients not well-con-
trolled on antiinflammatories alone. OBJECTIVE: To
estimate the association between type of asthma mainte-
nance therapy (anti-inflammatory versus bronchodilator)
and total costs of asthma treatment. METHODS: Pa-
tients were selected from the Asthma Outcomes Registry
cohort if they had received either antiinflammatories (in-
haled steroids or cromones) or long-acting bronchodila-
tors (theophylline, long-acting beta-agonists, or ipratro-
pium), but not both, for at least one year prior to study
entry. Oral steroid dependent patients and those with in-
complete cost data during the baseline and follow-up in-
tervals (365 days before and after their enrollment in the
Registry, respectively) were excluded from the analysis.
The effect of anti-inflammatory versus bronchodilator
therapy was assessed by comparing the change (follow-
up minus baseline) in the logarithm of total costs of
asthma care. RESULTS: 446 patient met criteria for
study inclusion, including 351 treated with anti-inflam-
matories and 95 treated with bronchodilators. Geometric
mean costs during the baseline year were similar in the
anti-inflammatory and bronchodilator groups ($358 and
$351, respectively). In the follow-up year, geometric
mean costs declined by $149 (to $209) in the anti-inflam-
matory group compared to an increase of $19 (to $340)
in the bronchodilator group (P  0.0001). This treat-
ment effect was essentially unaltered after adjustment for
study site, age, sex, smoking, and comorbidity. CON-
CLUSION: These findings add support to current guide-
lines recommending reliance on anti-inflammatory ther-
apy to control asthma. The emergence of new therapeutic
agents to control inflammation may continue to reduce
the costs of treating this important disease.
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OBJECTIVES: The purpose of this study is to examine
the effect of treatment with abciximab versus eptifibatide
or tirofiban during angioplasty on hospital length of stay
(LOS). METHODS: Hospital billing data for PTCAs per-
formed over a one year period (July 1998 to June 1999)
was obtained from HCIA’s Clinical Pathways Database.
Data was collected for all patient discharges whose
records indicated use of abciximab, eptifibatide, or
tirofiban. Results are reported for 6,637 patients. Multi-
variate analysis was used to control for a wide range of
factors (patient demographics, insurance, health condi-
tions, admission and discharge information, as well as
hospital characteristics) which may influence LOS. Esti-
mation was conducted via a two-stage sample selection
model. The first stage of the analysis utilizes a probit re-
gression to determine the factors associated with the like-
lihood of receiving abciximab. In the second stage of the
analysis a negative binomial model is estimated for pa-
tient’s LOS, while controlling for unobserved factors that
are correlated with the patient’s likelihood of receiving
abciximab. RESULTS: The average LOS for PTCA pa-
tients was 3.48 days. After controlling for high risk indi-
cations and selection bias, PTCA patients who were given
abciximab had a significantly shorter LOS than patients
who were administered eptifibatide (0.981 fewer days
0.243) or patients who were administered tirofiban
(0.934 fewer days 0.251). CONCLUSIONS: Results of
this study indicate that there are potential cost off-sets
for hospitals that administer abciximab versus eptifi-
batide or tirofiban, given the significantly shorter LOS
associated with patients who received abciximab.
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Parkinson’s Disease is a chronic neurodegenerative ill-
ness, which affects a significant number of elderly indi-
viduals. Typically, the process onset is between 45 to 65
years old individuals. The prevalence of Parkinson’s in a
managed care environment is unknown. OBJECTIVES:
After controlling for appropriate case mix variables (e.g.
age, gender, presence of selected comorbidities etc.) what
is the epidemiology and what is the cost of illness of Par-
kinson’s disease in a large healthcare plan? METHODS:
This was a retrospective database cost of illness study
consisting of all members with Parkinson’s (ICD-9
332.0) from 7/1/95 to 6/30/98. Members were screened
for continuous enrollment, medical, and drug coverage.
Members diagnosed prior to 7/1/95 were stratified as
prevalent cases. Medicare patients were excluded. The
database consisted of all pharmaceutical, professional,
laboratory, radiology, and institutional claims for ap-
proximately 1.38 million individuals from 1993 to the
present. The risk of contracting Parkinson’s, and healthcare
consumption, were analyzed by patient residence. RE-
SULTS: Parkinson’s risk was highest in urban areas, 3.69
cases per 1,000, compared to 2.24 for rural, and 1.80 for
suburban. Mean cost per patient per year (pppy) for the
disease was $2,161. Medical costs were higher at diagnosis
and decreased with escalating drug therapy. Medical costs
began at $3,120 pppy, dropped to $124 pppy after 12
months, but rose to $1192 pppy after 3 years. Pharmacy
costs began at $220 pppy, rose to $520 pppy after 12
months, and were $1796 pppy after 3 years. CONCLU-
SIONS: The incidence and prevalence of Parkinson’s in
this study matched nationally reported rates. Treatment
patterns and cost followed a logical progression towards
more drug therapy as the disease apparently worsened.
